Safety of prednisone for ocular myasthenia gravis. - Wikidata - wikimedia - TriplyDB

Safety of prednisone for ocular myasthenia gravis.

Safety of prednisone for ocular myasthenia gravis.

http://www.wikidata.org/entity/Q37063766

about

EFNS/ENS Guidelines for the treatment of ocular myasthenia.Glucocorticoids in myasthenia gravis - if, when, how, and how much?

P2860

Q38182650-6D6390FC-D68D-40B1-8E98-BF0CBC4B8A8E Q38234725-FC045C8D-86E2-4399-AD71-B3160C07241E

P2860

Safety of prednisone for ocular myasthenia gravis.

http://www.wikidata.org/entity/Q37063766

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Safety of prednisone for ocular myasthenia gravis.

@en

Safety of prednisone for ocular myasthenia gravis.

@nl

type

label

Safety of prednisone for ocular myasthenia gravis.

@en

Safety of prednisone for ocular myasthenia gravis.

@nl

prefLabel

Safety of prednisone for ocular myasthenia gravis.

@en

Safety of prednisone for ocular myasthenia gravis.

@nl

P1433

Q37063766-125DBBC6-80B3-4991-BFA3-3E9F9EF3B3C0

P1476

Q37063766-8257223A-33A4-4669-A39A-28622FFC0EE0

P2093

Q37063766-D811BF5F-E6F9-44EF-A724-85F1ED83D486

P2860

Q37063766-0352AC5C-D70F-4DBB-AB9D-D11F6D628B45

Q37063766-39D8AA93-8A56-415A-AB58-DD959CB62DF6

Q37063766-3D26B112-1BC5-4F6A-B377-6372CE567D60

Q37063766-59ACFE86-ABF3-4217-8312-E4D7C2144B3F

Q37063766-63113424-FC3C-457B-8630-5D0FC4E4131D

Q37063766-795D5FE2-979E-4C3E-9CEF-CF59DF69C58A

Q37063766-79C5CB3F-E58D-4142-9496-4C5FA7E80B26

Q37063766-8DA60BB4-5FF5-4BC6-8E39-72C33DBC60EB

Q37063766-A9FAB575-7267-400C-B0C8-FB3BC5CF23E9

Q37063766-B2E1783D-6E75-499F-A836-CD93DB41117A

P304

Q37063766-A3E31F97-39A1-4C66-A1D7-432D521495A0

P31

Q37063766-69E89384-478D-4644-A988-3EA4E1251BEB

P356

Q37063766-4FDFA739-ED38-450E-8E8E-6DFFBEA4F57F

P433

Q37063766-F945B971-959C-4FDA-8260-2388E3F37533

P478

Q37063766-775B86E6-6011-47E4-96D4-15916188A6D6

P50

Q37063766-4BFB93F3-BAE0-4A38-9357-F350DA68EAD7

P577

Q37063766-09C8A713-181C-4288-8CDF-ABBEE5A62B0B

P698

Q37063766-E67396ED-445A-4F3B-97A1-24435CB52034

P921

Q37063766-9E6E3EF0-AA9E-4B04-9141-67420F666A50

P932

Q37063766-809A1D1A-E52C-4DBF-B55A-9A2957057EAD

P356

WNO.0B013E3182536558

P1433

Journal of Neuro-Ophthalmology

P1476

Safety of prednisone for ocular myasthenia gravis

@en

P2093

Mark J Kupersmith

http://www.w3.org/2001/XMLSchema#string

P2860

Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment

Treatment of ocular myasthenia: steroids only when compelled

Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.

Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.

Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Steroids and immunosuppressant drugs in myasthenia gravis.

The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis.

Development of generalized disease at 2 years in patients with ocular myasthenia gravis.

Oral corticosteroids in the treatment of ocular myasthenia gravis.

P304

212-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/WNO.0B013E3182536558

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22549563

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

3731151

http://www.w3.org/2001/XMLSchema#string